Lisocabtagene maraleucel granted FDA approval for the treatment of R/R CLL/SLL
On March 14, 2024, the U.S. FDA approved lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with R/R CLL/SLL.
On March 14, 2024, the U.S. FDA approved lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with R/R CLL/SLL.
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Pancreatic Cancer statistics
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
With an FDA orphan drug designation now granted to IGNK001, clinical trials investigating the agent in acute myeloid leukemia are planned to initiate in the…
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo…